Azenta Sells B Medical Systems to Focus on Core Life Sciences Capabilities

Strategic Realignment: Azenta Focuses on Core Capabilities

Azenta, Inc. is taking decisive steps to refine its business portfolio by finalizing a binding agreement to sell its B Medical Systems business to THELEMA S.À R.L. for $63 million. This agreement, which is set to close by March 31, 2026, marks a significant move in Azenta's strategy to streamline operations and concentrate on its core competencies in life sciences solutions. John Marotta, President and CEO of Azenta, highlights that the proceeds from this sale will be strategically reinvested to bolster the company's strengths and create long-term value for stakeholders. By divesting from B Medical Systems, which specializes in medical refrigeration devices, Azenta aims to sharpen its focus on areas that deliver the greatest impact.

The sale of the B Medical Systems segment not only aligns with Azenta's strategy of focusing on high-value operations but also reflects the company's commitment to enhancing its cold-chain sample management solutions. These solutions are essential for the pharmaceutical and biotech sectors, particularly in the realms of drug development, clinical research, and advanced cell therapies. By divesting from a peripheral business, Azenta positions itself to further enhance its offerings in multiomics services and cold-chain logistics, which are critical components in ensuring the integrity of biological samples and data in research and development.

Azenta's decision is indicative of broader trends in the life sciences industry, where companies are increasingly prioritizing core competencies to remain competitive. The company’s extensive global reach, with operations in North America, Europe, and Asia, enables it to serve prominent pharmaceutical, biotech, academic, and healthcare institutions effectively. As Azenta transitions away from the medical refrigeration segment, its focus shifts entirely to areas that promise robust growth and innovation, ensuring that it remains a leader in delivering essential life sciences solutions.

In addition to the strategic sale, Azenta engages William Blair as its exclusive financial advisor and Taylor Wessing as legal counsel for this transaction. The company advises stakeholders to approach forward-looking statements with caution, acknowledging the inherent risks and uncertainties that could affect future outcomes. This divestiture is a pivotal moment for Azenta as it continues to adapt and innovate within the rapidly evolving life sciences landscape.

For more information about Azenta's ongoing initiatives and services, interested parties are encouraged to visit the company’s website at www.azenta.com.